PODD Stock Summary and Trading Ideas (Insulet | NASDAQ:PODD)

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Insulet trades on the NASDAQ stock market under the symbol PODD.

As of November 12, 2026, PODD stock price declined to $149.29 with 657,813 million shares trading.

PODD has a beta of -0.67, meaning it tends to be less sensitive to market movements. PODD has a correlation of 0.05 to the broad based SPY ETF.

PODD has a market cap of $10.51 billion. This is considered a Large Cap stock.

Last quarter Insulet reported $842 million in Revenue and $1.99 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.40.

In the last 3 years, PODD traded as high as $354.88 and as low as $126.40.

The top ETF exchange traded funds that PODD belongs to (by Net Assets): VTI, VOO, RSP, VB, IVV.

PODD has underperformed the market in the last year with a price return of -55.7% while the SPY ETF gained +11.9%. However, in the short term, PODD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +2.9% vs -1.7% return in SPY. But in the last 2 weeks, PODD shares have been beat by the market, returning -2.1% compared to an SPY return of -1.6%.

PODD support price is $146.45 and resistance is $153.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PODD shares will trade within this expected range on the day.